News
JBIO
16.14
+1.70%
0.27
Is Jade Biosciences (JBIO) Fully Valued On Book Value Today?
Simply Wall St · 22h ago
Jade Biosciences GAAP EPS of -$0.42
Seeking Alpha · 1d ago
Jade Biosciences Q3 EPS $(0.42) Beats $(0.71) Estimate
Benzinga · 1d ago
*Jade Biosciences 3Q Loss/Shr 42c >JBIO
Dow Jones · 1d ago
*Jade Biosciences 3Q Research and Development Expenses $30.8M >JBIO
Dow Jones · 1d ago
Press Release: Jade Biosciences Reports Third -2-
Dow Jones · 1d ago
Press Release: Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 1d ago
Jade Biosciences (JBIO) Stock Dropped, So What Is Driving Attention Now?
Simply Wall St · 1d ago
Jade Biosciences Updates Early JADE101 Study as Investors Await Results
TipRanks · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 4d ago
Weekly Report: what happened at JBIO last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at JBIO last week (1026-1030)?
Weekly Report · 11/02 10:25
Jade Biosciences Price Target Maintained With a $77.00/Share by BTIG
Dow Jones · 10/27 10:47
BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price Target
Benzinga · 10/27 09:45
JBIO: Buy Rating Reiterated as Analyst Highlights JADE Pipeline Strength and Maintains $77 Price Target
TipRanks · 10/27 00:45
Weekly Report: what happened at JBIO last week (1019-1023)?
Weekly Report · 10/26 10:24
Jade Biosciences Advances First-in-Human RA Trial, Setting Up Early Read on Pipeline Value
TipRanks · 10/23 16:30
Jade Biosciences management to meet with BTIG
TipRanks · 10/19 19:45
Weekly Report: what happened at JBIO last week (1012-1016)?
Weekly Report · 10/19 10:24
Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Jade Biosciences (JBIO)
TipRanks · 10/16 11:40
More
Webull provides a variety of real-time JBIO stock news. You can receive the latest news about Jade Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About JBIO
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.